

Piet L C M Van Riel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1302320/publications.pdf>

Version: 2024-02-01

68
papers

7,466
citations

279798

23
h-index

102487

66
g-index

71
all docs

71
docs citations

71
times ranked

12123
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
3	Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. <i>Pain</i> , 2002, 100, 141-153.	4.2	239
4	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
5	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 48-54.	0.9	194
6	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 998-1003.	0.9	121
7	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
8	Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. <i>Rheumatology</i> , 2017, 56, 1102-1110.	1.9	100
9	The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S40-S44.	0.8	100
10	Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 479-488.	3.4	98
11	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	5.6	70
12	Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 134.	3.5	57
13	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	3.8	57
14	Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1683-1688.	0.9	49
15	Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0174656.	2.5	38
16	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	3.5	37
17	DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, 189.	3.5	35
18	Patient Self-Management and Tracking. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 187-195.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Calibration of the PROMIS Physical Function Item Bank in Dutch Patients with Rheumatoid Arthritis. PLoS ONE, 2014, 9, e92367.	2.5	30
20	Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology, 2020, 59, 1997-2004.	1.9	29
21	Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. Rheumatology, 2015, 54, kev265.	1.9	28
22	Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2183-2187.	0.9	27
23	Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization. Rheumatology Advances in Practice, 2021, 5, rkaa079.	0.7	27
24	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843.	2.0	21
25	Immune responses to stress in rheumatoid arthritis and psoriasis. Rheumatology, 2014, 53, 1844-1848.	1.9	20
26	Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care. Annals of the Rheumatic Diseases, 2018, 77, 480-483.	0.9	20
27	Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. Rheumatology, 2017, 56, 1560-1565.	1.9	19
28	Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 3191-3199.	2.2	19
29	Assessment of Fatigue in Rheumatoid Arthritis: A Psychometric Comparison of Single-item, Multiitem, and Multidimensional Measures. Journal of Rheumatology, 2015, 42, 413-420.	2.0	18
30	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. Arthritis and Rheumatology, 2018, 70, 1557-1564.	5.6	17
31	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS ONE, 2018, 13, e0192425.	2.5	17
32	Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare. RMD Open, 2015, 1, e000114.	3.8	14
33	Established rheumatoid arthritis: clinical assessments. Best Practice and Research in Clinical Rheumatology, 2007, 21, 807-825.	3.3	13
34	A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 200-6.	0.8	13
35	Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. Rheumatology, 2015, 54, 1080-1086.	1.9	12
36	The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions. Joint Bone Spine, 2015, 82, 470-471.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1787-1794.	2.0	12
38	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
39	Quality in rheumatoid arthritis care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 664-679.	3.3	11
40	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. <i>Journal of Rheumatology</i> , 2015, 42, 398-404.	2.0	11
41	Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e24-e24.	0.9	11
42	Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. <i>RMD Open</i> , 2015, 1, e000147.	3.8	11
43	Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related). <i>Current Medical Research and Opinion</i> , 2017, 33, 1231-1246.	1.9	11
44	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <i>Arthritis Research and Therapy</i> , 2020, 22, 90.	3.5	11
45	Impaired <i>Porphyromonas gingivalis</i> -Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 795-804.	5.6	10
46	Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease. <i>Arthritis Care and Research</i> , 2018, 70, 516-524.	3.4	10
47	The influence of patient perceptions of disease on medication intensification in daily practice. <i>Rheumatology</i> , 2016, 55, 1938-1945.	1.9	9
48	Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 175-182.	3.4	8
49	One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa042.	0.7	8
50	Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e260.	4.3	8
51	Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	7
52	Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?. <i>Journal of Rheumatology</i> , 2021, 48, 1803-1809.	2.0	7
53	Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis: results from a questionnaire survey of expert rheumatology centers. <i>Rheumatology International</i> , 2020, 40, 523-527.	3.0	7
54	Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis Taking Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 1263-1269.	2.0	6

#	ARTICLE	IF	CITATIONS
55	A Simplified Baseline Prediction Model for Joint Damage Progression in Rheumatoid Arthritis: A Step toward Personalized Medicine. <i>Journal of Rheumatology</i> , 2015, 42, 391-397.	2.0	6
56	A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease. <i>Joint Bone Spine</i> , 2017, 84, 709-713.	1.6	6
57	Evaluating quality of care in rheumatoid arthritis: the patient perspective. <i>RMD Open</i> , 2017, 3, e000411.	3.8	5
58	Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era. <i>Patient Education and Counseling</i> , 2018, 101, 67-73.	2.2	5
59	Biosimilars in the management of chronic inflammatory diseases: The Dutch experience. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 76.	0.8	5
60	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	1.6	4
61	The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists. <i>Journal of Rheumatology</i> , 2020, 47, 290-297.	2.0	3
62	Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade. <i>Clinical Rheumatology</i> , 2020, 39, 1131-1139.	2.2	2
63	Co-Design of a Disease Activity Based Self-Management Approach for Patients with Rheumatoid Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 21.	0.8	2
64	Exercise participation has increased in patients with Rheumatoid Arthritis: A cross-sectional comparison between two Dutch RA cohorts. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 199-206.	0.8	2
65	A different perspective: Inflammatory rheumatic diseases and other organs. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 787-788.	3.3	1
66	SAT0109...SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AND IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY. , 2019, , .		0
67	Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial. <i>Rheumatology</i> , 2020, 59, 1170-1171.	1.9	0
68	Two parallel short forms to measure disease- and treatment-associated knowledge in rheumatoid arthritis: application of item response theory. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa012.	0.7	0